Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer

Bruno de Paula, Eliana Abdelhay, Carlos Augusto Moreira de Sousa, Susanne Crocamo